Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Connection

Paul Norman to HLA-B Antigens

This is a "connection" page, showing publications Paul Norman has written about HLA-B Antigens.

 
Connection Strength
 
 
 
3.139
 
  1. Cline N, Merlo D, Frater S, Pollock NR, Mayor NP, Turner TR, Walsh L, Vivers S, Norman PJ. The Case of a Missing HLA-B Gene. HLA. 2025 Mar; 105(3):e70114.
    View in: PubMed
    Score: 0.933
  2. Nemat-Gorgani N, Edinur HA, Hollenbach JA, Traherne JA, Dunn PP, Chambers GK, Parham P, Norman PJ. KIR diversity in Maori and Polynesians: populations in which HLA-B is not a significant KIR ligand. Immunogenetics. 2014 Nov; 66(11):597-611.
    View in: PubMed
    Score: 0.450
  3. Harrison GF, Leaton LA, Harrison EA, Kichula KM, Viken MK, Shortt J, Gignoux CR, Lie BA, Vukcevic D, Leslie S, Norman PJ. Allele imputation for the killer cell immunoglobulin-like receptor KIR3DL1/S1. PLoS Comput Biol. 2022 02; 18(2):e1009059.
    View in: PubMed
    Score: 0.189
  4. Deng Z, Zhen J, Harrison GF, Zhang G, Chen R, Sun G, Yu Q, Nemat-Gorgani N, Guethlein LA, He L, Tang M, Gao X, Cai S, Palmer WH, Shortt JA, Gignoux CR, Carrington M, Zou H, Parham P, Hong W, Norman PJ. Adaptive Admixture of HLA Class I Allotypes Enhanced Genetically Determined Strength of Natural Killer Cells in East Asians. Mol Biol Evol. 2021 05 19; 38(6):2582-2596.
    View in: PubMed
    Score: 0.179
  5. Elfishawi M, Mossallam G, Augusto DG, Montero-Martin G, de Bruin H, Van de Pasch L, Norman PJ, Rozemuller E, Fernandez-Vina M, Abrudescu A, Hollenbach JA, Zaky K, Elfishawi S. Beh?et disease, new insights in disease associations and manifestations: a next-generation sequencing study. Clin Exp Immunol. 2021 04; 204(1):144-151.
    View in: PubMed
    Score: 0.176
  6. Nemat-Gorgani N, Guethlein LA, Henn BM, Norberg SJ, Chiaroni J, Sikora M, Quintana-Murci L, Mountain JL, Norman PJ, Parham P. Diversity of KIR, HLA Class I, and Their Interactions in Seven Populations of Sub-Saharan Africans. J Immunol. 2019 05 01; 202(9):2636-2647.
    View in: PubMed
    Score: 0.155
  7. Robinson J, Guethlein LA, Cereb N, Yang SY, Norman PJ, Marsh SGE, Parham P. Distinguishing functional polymorphism from random variation in the sequences of >10,000 HLA-A, -B and -C alleles. PLoS Genet. 2017 Jun; 13(6):e1006862.
    View in: PubMed
    Score: 0.137
  8. Ashouri E, Norman PJ, Guethlein LA, Han AS, Nemat-Gorgani N, Norberg SJ, Ghaderi A, Parham P. HLA class I variation in Iranian Lur and Kurd populations: high haplotype and allotype diversity with an abundance of KIR ligands. HLA. 2016 09; 88(3):87-99.
    View in: PubMed
    Score: 0.129
  9. Norman PJ, Hollenbach JA, Nemat-Gorgani N, Marin WM, Norberg SJ, Ashouri E, Jayaraman J, Wroblewski EE, Trowsdale J, Rajalingam R, Oksenberg JR, Chiaroni J, Guethlein LA, Traherne JA, Ronaghi M, Parham P. Defining KIR and HLA Class I Genotypes at Highest Resolution via High-Throughput Sequencing. Am J Hum Genet. 2016 Aug 04; 99(2):375-91.
    View in: PubMed
    Score: 0.129
  10. Alicata C, Pende D, Meazza R, Canevali P, Loiacono F, Bertaina A, Locatelli F, Nemat-Gorgani N, Guethlein LA, Parham P, Moretta L, Moretta A, Bottino C, Norman PJ, Falco M. Hematopoietic stem cell transplantation: Improving alloreactive Bw4 donor selection by genotyping codon 86 of KIR3DL1/S1. Eur J Immunol. 2016 06; 46(6):1511-7.
    View in: PubMed
    Score: 0.127
  11. Abi-Rached L, Jobin MJ, Kulkarni S, McWhinnie A, Dalva K, Gragert L, Babrzadeh F, Gharizadeh B, Luo M, Plummer FA, Kimani J, Carrington M, Middleton D, Rajalingam R, Beksac M, Marsh SG, Maiers M, Guethlein LA, Tavoularis S, Little AM, Green RE, Norman PJ, Parham P. The shaping of modern human immune systems by multiregional admixture with archaic humans. Science. 2011 Oct 07; 334(6052):89-94.
    View in: PubMed
    Score: 0.091
  12. Sanjanwala B, Draghi M, Norman PJ, Guethlein LA, Parham P. Polymorphic sites away from the Bw4 epitope that affect interaction of Bw4+ HLA-B with KIR3DL1. J Immunol. 2008 Nov 01; 181(9):6293-300.
    View in: PubMed
    Score: 0.075
  13. Norman PJ, Abi-Rached L, Gendzekhadze K, Korbel D, Gleimer M, Rowley D, Bruno D, Carrington CV, Chandanayingyong D, Chang YH, Cresp? C, Saruhan-Direskeneli G, Fraser PA, Hameed K, Kamkamidze G, Koram KA, Layrisse Z, Matamoros N, Mil? J, Park MH, Pitchappan RM, Ramdath DD, Shiau MY, Stephens HA, Struik S, Verity DH, Vaughan RW, Tyan D, Davis RW, Riley EM, Ronaghi M, Parham P. Unusual selection on the KIR3DL1/S1 natural killer cell receptor in Africans. Nat Genet. 2007 Sep; 39(9):1092-9.
    View in: PubMed
    Score: 0.069
  14. Tao S, You X, Norman PJ, Kichula KM, Dong L, Chen N, He J, Zhang W, Zhu F. Analysis of KIR and HLA Polymorphism in Chinese Individuals With COVID-19. HLA. 2024 10; 104(4):e15715.
    View in: PubMed
    Score: 0.057
  15. Ahn R, Vukcevic D, Motyer A, Nititham J, Squire DM, Hollenbach JA, Norman PJ, Ellinghaus E, Nair RP, Tsoi LC, Oksenberg J, Foerster J, Lieb W, Weidinger S, Franke A, Elder JT, Jorgenson E, Leslie S, Liao W. Large-Scale Imputation of KIR Copy Number and HLA Alleles in North American and European Psoriasis Case-Control Cohorts Reveals Association of Inhibitory KIR2DL2 With Psoriasis. Front Immunol. 2021; 12:684326.
    View in: PubMed
    Score: 0.045
  16. Anderson KM, Augusto DG, Dandekar R, Shams H, Zhao C, Yusufali T, Montero-Mart?n G, Marin WM, Nemat-Gorgani N, Creary LE, Caillier S, Mofrad MRK, Parham P, Fern?ndez-Vi?a M, Oksenberg JR, Norman PJ, Hollenbach JA. Killer Cell Immunoglobulin-like Receptor Variants Are Associated with Protection from Symptoms Associated with More Severe Course in Parkinson Disease. J Immunol. 2020 09 01; 205(5):1323-1330.
    View in: PubMed
    Score: 0.042
  17. Pugh J, Nemat-Gorgani N, Djaoud Z, Guethlein LA, Norman PJ, Parham P. In vitro education of human natural killer cells by KIR3DL1. Life Sci Alliance. 2019 12; 2(6).
    View in: PubMed
    Score: 0.040
  18. Petrushkin H, Norman PJ, Lougee E, Parham P, Wallace GR, Stanford MR, Fortune F. KIR3DL1/S1 Allotypes Contribute Differentially to the Development of Beh?et Disease. J Immunol. 2019 09 15; 203(6):1629-1635.
    View in: PubMed
    Score: 0.040
  19. Wroblewski EE, Guethlein LA, Norman PJ, Li Y, Shaw CM, Han AS, Ndjango JN, Ahuka-Mundeke S, Georgiev AV, Peeters M, Hahn BH, Parham P. Bonobos Maintain Immune System Diversity with Three Functional Types of MHC-B. J Immunol. 2017 May 01; 198(9):3480-3493.
    View in: PubMed
    Score: 0.034
  20. Parham P, Norman PJ, Abi-Rached L, Guethlein LA. Variable NK cell receptors exemplified by human KIR3DL1/S1. J Immunol. 2011 Jul 01; 187(1):11-9.
    View in: PubMed
    Score: 0.023
  21. Sharma D, Bastard K, Guethlein LA, Norman PJ, Yawata N, Yawata M, Pando M, Thananchai H, Dong T, Rowland-Jones S, Brodsky FM, Parham P. Dimorphic motifs in D0 and D1+D2 domains of killer cell Ig-like receptor 3DL1 combine to form receptors with high, moderate, and no avidity for the complex of a peptide derived from HIV and HLA-A*2402. J Immunol. 2009 Oct 01; 183(7):4569-82.
    View in: PubMed
    Score: 0.020
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)